Sandoz, Novartis’ generics business, has announced that it is in the process of selling or discontinuing some products in the United States.
“In response to high price pressure, we are optimizing our U.S. portfolio. This includes the sale or discontinuation of certain non-core products and concentration of investment in strategic areas that will drive growth and improve access,” Sandoz told Swiss newspaper, Handelszeitung.
It is still unclear which drugs would be affected by a potential sale.
Third quarter sales for Sandoz were down 10 percent, according to Handelszeitung.